

The last day of trading with the warrants of series T06 in Lumito AB is today, November 12, 2024

Today, November 12, 2024, is the last day of trading with the warrants of series T06 in Lumito AB (publ) ("Lumito" or the "Company"). The exercise period for the warrants runs up to and including November 15, 2024. Each warrant of series T06 gives the owner the right to subscribe for one (1) new share in the Company for a subscription price of SEK 0.39 per share.

Summarized terms for the warrants of series T06:

Exercise period: November 4, 2024 – November 15, 2024.

Subscription price: SEK 0.39 per share.

Issue volume: 34,406,248 warrants of series T06 entitles to subscription of 34,406,248 shares. If all warrants are exercised the Company will receive approximately SEK 13.4 million before issuing costs.

Last day for trading with warrants: November 12, 2024.

Share capital and dilution: If all warrants of series T06 are exercised the number of shares will increase with 34,406,248 shares from 233,691,423 shares to 268,097,671 shares and the share capital will increase with SEK 860,156.20, from SEK 5,842,285.58 to SEK 6,702,441.78, corresponding to a maximal dilution effect of 12.8 percent if the number of shares.

Note that the warrants that are not exercised at the latest November 15, 2024, or sold at the latest November 12, 2024, will expire without value. For the warrants of series T06 not to lose their value, the holder must actively subscribe for new shares or sell the warrants. Please note that some nominees may close registration earlier than November 15, 2024.

Advisers

Mangold Fondkommission AB is financial adviser and Advokatfirman Lindahl KB is legal advisor to Lumito in connection with the exercise of the warrants of series T06.

For further information, please contact:

Sanna Wallenborg, CEO Lumito

E-mail: sw@lumito.se

Ph: +4670-870 01 68

About Lumito

Lumito specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre. www.lumito.se/en

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments

[The last day of trading with the warrants of series TO6 in Lumito AB is today, November 12, 2024](#)